OS Therapies Incorporated
AMEX: OSTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul A. Romness
- Employees
- 5
- Headquarters
- Grasonville, United States
- IPO year
- 2024
- Market cap
- $80.6M
- Website
- https://ostherapies.com
Loading OSTX…
Loading profile data…Frequently asked questions about OSTX
What does OS Therapies Incorporated (OSTX) do?
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), a...
Where does OSTX trade?
OS Therapies Incorporated (OSTX) trades on the New York Stock Exchange American.
What sector is OSTX in?
OS Therapies Incorporated (OSTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OS Therapies Incorporated?
Paul A. Romness is the chief executive officer of OS Therapies Incorporated (OSTX).
Where is OS Therapies Incorporated headquartered?
OS Therapies Incorporated is headquartered in United States.
Does OSTX pay a dividend?
OS Therapies Incorporated (OSTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OSTX go public?
OS Therapies Incorporated (OSTX) completed its initial public offering in 2024.